Skip to main content
Fig. 4 | BMC Bioinformatics

Fig. 4

From: A comparison of embedding aggregation strategies in drug–target interaction prediction

Fig. 4

Plot of the capacity of different models against their test MSE. All the points represent experiments with an MPNN as the compound branch and a CNN as the protein branch. The point colored green represents a well-performing experiment of the MLP strategy, while the blue points represent dot product strategies with similar branch configurations. The results illustrate the inability of the dot product to achieve comparable performance with the MLP strategy when one of the branches fails to utilize its input properly. Even after testing dot-product-based configurations with varying capacity (increasing the MPNN depth) exceeding that of the MLP benchmark, the performance does not improve. Our hypothesis is that the main reason for the underperforming experiments that use the dot product is the over-smoothing effect that graph neural networks suffer from. This assumption is supported by the significant improvements that a small modification attains (colored red). Instead of increasing the capacity of the MPNN directly, we instead append fully-connected layers immediately after it and before the embedding aggregation operation, thus increasing the overall capacity of the compound branch and bypassing the MPNN. The experiments colored red demonstrate that the dot product strategy can reach a comparable performance as the MLP strategy while keeping the overall capacity low

Back to article page